MARKET

OCUL

OCUL

Ocular Therapeut
NASDAQ
12.43
+0.97
+8.46%
After Hours: 12.40 -0.03 -0.25% 19:06 12/04 EST
OPEN
11.48
PREV CLOSE
11.46
HIGH
13.00
LOW
11.41
VOLUME
5.82M
TURNOVER
--
52 WEEK HIGH
13.85
52 WEEK LOW
5.79
MARKET CAP
2.65B
P/E (TTM)
-8.6542
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OCUL last week (1124-1128)?
Weekly Report · 4d ago
Ocular Therapeutix Executives Cash In on Stock Sales!
TipRanks · 11/27 02:03
SA Quant ranks Goldman's health care stocks with biggest increase in hedge fund popularity
Seeking Alpha · 11/25 21:19
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $19 Price Target
Benzinga · 11/25 11:43
Promising Developments in Ocular Therapeutix’s Clinical Trials Support Buy Rating
TipRanks · 11/25 11:26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 11/25 00:20
Analysts Are Bullish on Top Healthcare Stocks: Bioline RX Ltd Sponsored ADR (BLRX), Ocular Therapeutix (OCUL)
TipRanks · 11/24 20:00
Ocular Therapeutix announces first patient randomized in HELIOS-3 program
TipRanks · 11/24 12:25
More
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.

Webull offers Ocular Therapeutix Inc stock information, including NASDAQ: OCUL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OCUL stock methods without spending real money on the virtual paper trading platform.